Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783289 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00783289 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 35 participants.
The verdict
NCT00783289, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.
Interventions
- OTHER Placebo
- BIOLOGICAL Benralizumab 100 mg
- BIOLOGICAL Benralizumab 25 mg
- BIOLOGICAL Benralizumab 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-11-14 |
| Est. Completion | 2009-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00783289
The ClinicalTrials.gov registry entry for NCT00783289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00783289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00783289 about?
NCT00783289 is a clinical study titled "A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma". The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.
What is the current status of trial NCT00783289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-11-14. Estimated completion is 2009-11-17.
What interventions are being tested in trial NCT00783289?
The interventions under investigation include: Placebo (OTHER), Benralizumab 100 mg (BIOLOGICAL), Benralizumab 25 mg (BIOLOGICAL), Benralizumab 200 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00783289?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.